JPH07107055B1 - - Google Patents

Info

Publication number
JPH07107055B1
JPH07107055B1 JP3507543A JP50754391A JPH07107055B1 JP H07107055 B1 JPH07107055 B1 JP H07107055B1 JP 3507543 A JP3507543 A JP 3507543A JP 50754391 A JP50754391 A JP 50754391A JP H07107055 B1 JPH07107055 B1 JP H07107055B1
Authority
JP
Japan
Prior art keywords
salt
vasodilatory
cardiotonic
srs
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3507543A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1991016314A1 (ja
JPH07107055B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP3-507543A priority Critical patent/JPH07107055B2/ja
Publication of JPWO1991016314A1 publication Critical patent/JPWO1991016314A1/ja
Publication of JPH07107055B2 publication Critical patent/JPH07107055B2/ja
Publication of JPH07107055B1 publication Critical patent/JPH07107055B1/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP3-507543A 1990-04-25 1991-04-19 ピリダジノン誘導体 Expired - Lifetime JPH07107055B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3-507543A JPH07107055B2 (ja) 1990-04-25 1991-04-19 ピリダジノン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2-109914 1990-04-25
JP10991490 1990-04-25
JP3-507543A JPH07107055B2 (ja) 1990-04-25 1991-04-19 ピリダジノン誘導体

Publications (3)

Publication Number Publication Date
JPWO1991016314A1 JPWO1991016314A1 (ja) 1992-05-07
JPH07107055B2 JPH07107055B2 (ja) 1995-11-15
JPH07107055B1 true JPH07107055B1 (enExample) 1995-11-15

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3-507543A Expired - Lifetime JPH07107055B2 (ja) 1990-04-25 1991-04-19 ピリダジノン誘導体

Country Status (17)

Country Link
US (3) US5202323A (enExample)
EP (1) EP0482208B1 (enExample)
JP (1) JPH07107055B2 (enExample)
KR (1) KR970002876B1 (enExample)
AT (1) ATE194835T1 (enExample)
AU (1) AU634655B2 (enExample)
CA (1) CA2053863C (enExample)
DE (1) DE69132329T2 (enExample)
DK (1) DK0482208T3 (enExample)
ES (1) ES2149761T3 (enExample)
GR (1) GR3034331T3 (enExample)
HU (1) HU208124B (enExample)
RU (1) RU2054004C1 (enExample)
TW (1) TW204348B (enExample)
UA (1) UA27031A1 (enExample)
WO (1) WO1991016314A1 (enExample)
ZA (1) ZA913134B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
EP0717734B1 (en) * 1993-09-06 1998-11-18 Ishihara Sangyo Kaisha, Ltd. Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
TW326041B (en) * 1993-12-16 1998-02-01 Nippon Nouyaku Kk Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation
US5750523A (en) * 1994-01-25 1998-05-12 Nissan Chemical Industries, Ltd. Pyridazinone derivatives
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
CZ297769B6 (cs) 1996-06-27 2007-03-28 Janssen Pharmaceutica N. V. N-[4-(heteroarylmetyl)fenyl]-heteroarylaminy, zpusob jejich prípravy a jejich pouzití jako léciva
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
EP1025847B1 (en) 1997-08-28 2005-10-26 Nissan Chemical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
ATE272401T1 (de) * 1998-09-01 2004-08-15 Nissan Chemical Ind Ltd Heilmittel für die stenose des rückenmarkkanals
UA73104C2 (en) * 1998-12-07 2005-06-15 Nissan Chemical Ind Ltd Erectile dysfunction remedy comprising 3(2h)-pyridazinone derivative
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CA2439593C (en) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
CA2447618A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
RU2339381C2 (ru) * 2004-02-09 2008-11-27 Ниссан Кемикал Индастриз, Лтд. Ингибитор гиперплазии интимы сосудов
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2374805A4 (en) * 2008-12-25 2012-06-27 Nissan Chemical Ind Ltd PYRIDAZINE-3 (2H) -ONE HYDROCHLORIDE COMPOUND CRYSTALS AND METHOD FOR THE PRODUCTION THEREOF
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2535048A4 (en) 2010-02-12 2013-08-14 Taisho Pharmaceutical Co Ltd PREPARATION WITH DELAYED RELEASE
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
CA1265798A (en) * 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ZW20586A1 (en) * 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat

Also Published As

Publication number Publication date
UA27031A1 (uk) 2000-02-28
US5202323A (en) 1993-04-13
CA2053863A1 (en) 1991-10-26
RU2054004C1 (ru) 1996-02-10
TW204348B (enExample) 1993-04-21
US5318968A (en) 1994-06-07
AU634655B2 (en) 1993-02-25
KR920701169A (ko) 1992-08-11
HU913497D0 (en) 1992-01-28
EP0482208A1 (en) 1992-04-29
JPH07107055B2 (ja) 1995-11-15
ES2149761T3 (es) 2000-11-16
HUT60253A (en) 1992-08-28
DE69132329T2 (de) 2000-11-30
ZA913134B (en) 1992-04-29
DK0482208T3 (da) 2000-09-18
WO1991016314A1 (en) 1991-10-31
US5314883A (en) 1994-05-24
CA2053863C (en) 1996-10-29
DE69132329D1 (de) 2000-08-24
HU208124B (en) 1993-08-30
EP0482208A4 (en) 1992-10-07
ATE194835T1 (de) 2000-08-15
EP0482208B1 (en) 2000-07-19
KR970002876B1 (ko) 1997-03-12
AU7651191A (en) 1991-11-11
GR3034331T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
JPH07107055B1 (enExample)
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
MY106280A (en) Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use.
AU7815791A (en) Heterocyclene derivatives
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
HUT56073A (en) Process for producing perhydroisoquinoline amino acid derivatives and pharmaceutical compositions comprising same
MY112102A (en) Therapeutic heterocycles.
AP9701041A0 (en) Pyridylpyrrole compounds.
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
AU7436691A (en) Novel 2,9-disubstituted-4H-pyrido(1,2-a)pyrimidin-4-ones
GB9502644D0 (en) Heterocyclic derivatives
AU1115895A (en) Bicyclic heterocycles as neurokinin a antagonists
NO173444C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 4-(4'- fluorfenyl-)-tienopyridin-derivater
CA2016551A1 (en) Thieno-triazolo-diazepine derivatives, a preparation process of the same and therapeutic compositions containing them
CA2176144A1 (en) Anthracycline derivatives for treatment of amyloidosis
ZA979647B (en) Heterocyclic compounds, compositions and uses.
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments
IL133222A0 (en) Pharmaceutical compositions containing cinchonine dichlorohydrate
ATE10934T1 (de) Peptid, verfahren zu dessen herstellung und dessen verwendung.
JO1648B1 (en) Nitrogen compounds
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071115

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081115

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081115

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091115

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101115

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101115

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111115

Year of fee payment: 16

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111115

Year of fee payment: 16